How would specific basal insulin-GLP-1 RA combination agents be used in specific patient populations with T2D? Are there trials that shed light on this?

How would specific basal insulin-GLP-1 RA combination agents be used in specific patient populations with T2D? Are there trials that shed light on this?

How would specific basal insulin-GLP-1 RA combination agents be used in specific patient populations with T2D? Are there trials that shed light on this?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Pablo Mora, MD

Pablo Mora, MD

Diabetes America
Staff Endocrinologist
Division of Endocrinology, Diabetes and Metabolism
University of Texas Southwestern Medical Center
Plano, Texas